Search Results

Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Clementia Pharmaceuticals, Inc. in connection with the proposed acquisition of the Company by French drugmaker Ipsen.

This morning, Ipsen said it entered into an agreement with Clementia will help the company continue its transformation that is part of a key strategic objective to accelerate its rare disease pipeline.

As of September 30, 2017, Clementia had cash and investments of $152.2 million, which includes the $128.2 million raised in Clementia’s IPO completed in August.

Clementia Pharmaceuticals Inc. is pleased to announce that it has obtained an interim order from the Québec Superior Court in connection with the previously announced plan of arrangement pursuant to which a wholly-owned subsidiary of Ipsen S.A. is proposing to acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share.

Palovarotene, Clementia’s lead product candidate, is a retinoic acid receptor gamma agonist being investigated as a treatment for patients with ultra-rare and debilitating bone diseases.

Clementia Pharmaceuticals Inc. today announced the initiation of a Phase 1 clinical trial evaluating an eye drop formulation of palovarotene in healthy volunteers.

Ipsen’s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients

Management will host a conference call and webcast at 8:30 a.m. ET on Tuesday, Dec. 12, 2017.